FDA advisers are voting on Grail's multicancer blood test as Medicare coverage hangs in the balance

The Molecular and Clinical Genetics Panel is weighing the Galleri test's clinical evidence today; Medicare coverage could follow FDA approval

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (qz.com)